Introduction
Sirolimus (rapamycin, rapamune) is an agent used as an alternative immunosuppressive therapy in solid organ as well as in hematopoietic cell transplantation (HCT). [1] [2] [3] Sirolimus inhibits cytokine-driven signaling pathways of the T cells via blockade of the mammalian target of rapamycin, and specifically inhibits the progression of cells from the G1 phase to the S phase. 4 In combination with FK506 in the HCT setting, sirolimus may reduce the incidence of acute GVHD (AGVHD) while decreasing the severity and incidence of mucositis and CMV reactivation as compared with MTX-containing regimens. 3, 5, 6 Unfortunately, these encouraging results have been diminished by significant risks of renal failure, thrombotic microangiopathy (TMA) and sinusoidal obstructive syndrome (SOS) observed with the sirolimus and calcineurin inhibitor (CNI) combination in GVHD prophylactic, AGVHD and chronic GVHD treatment trials. 2, [7] [8] [9] [10] Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5 0 -monophosphate dehydrogenase, the enzyme controlling the rate-limiting step in de novo purine nucleotide synthesis in T and B lymphocytes. 11 As with the use of sirolimus, MMF has been incorporated into the solid organ transplant immunosuppressive regimens with the goals of maintaining and/or improving graft and patient survival while minimizing or eliminating the use of CNIs and corticosteroids. [12] [13] [14] MMF has been used in HCT as treatment and prevention of AGVHD and chronic GVHD with historical comparisons as well as a randomized trial supporting reduced mucositis and less cytopenias compared with MTX-containing prophylactic regimens and similar AGVHD incidence. [15] [16] [17] [18] [19] [20] With the goals of reducing the incidence and severity of AGVHD and minimizing the toxicities seen with CNIcontaining GVHD prophylactic regimens, we conducted a phase II trial of GVHD prophylaxis of sirolimus and MMF. In addition, intriguing evidence suggests sirolimus and MMF may conserve the inhibition of T-cell proliferation compared with CYA in an AGVHD murine model as well as reports supporting preservative or augmentative effects of sirolimus on regulatory T (CD4 þ CD25 þ FoxP3 þ ; T reg ) cells in animals and humans in comparison with CYA. 21 Hence, our study also included the prospective analysis of the T reg cell populations in the peripheral blood (PB) of the patients receiving the sirolimus and MMF GVHD prophylactic regimen.
Materials and methods

Patient eligibility
Patients 2-61 years of age with a diagnosis of high-risk hematological malignancy were eligible; however, at the closure of this trial, there were no pediatric patients enrolled. The diagnoses included AML and ALL beyond first CR or with relapsed or refractory disease; patients age 51-60 in XCR1 or with relapsed or refractory disease; patients age 2-61 years with myelodysplasia (MDS) World Health Organization-1, World Health Organization-2 or secondary MDS; non-Hodgkin lymphoma XCR1 receiving a myeloablative HCT with an identified 6/6 HLA-A, B and DRB1 matched-related donor were eligible for this phase II clinical trial. Patients were required to have a Karnofsky performance status of X70%, no evidence of uncontrolled infections, adequate organ function, fasting cholesterol p300 mg/dL and triglycerides p300 mg/dL while on lipid lowering agents and no previous myeloablative HCT. Pregnant or HIV-positive patients were not eligible. The study protocol was approved by the Institutional Review Board at Stanford University and all patients gave written informed consent.
A control group of 15 adult HCT recipients of myeloablative, matched-related donor PBSC transplantation was chosen based on receiving non-sirolimus-containing GVHD prophylaxis. These control patients underwent HCT via Institutional Review Board-approved clinical trials after written informed consent.
Treatment regimen
Eligible patients received one of three myeloablative preparative regimens based on their age and hematological malignancy: (1) patients aged 18-60 years with lymphoma: BCNU, 15 mg/kg (maximum dose 550 mg/m 2 actual body weight) on day À6, etoposide, 60 mg/kg on day À4 and CY, 100 mg/kg on day À2; 22 (2) patients aged 18-50 years with AML, ALL or CML: TBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days À8 through À5, etoposide 60 mg/kg on day À4, CY 60 mg/kg on day À2; 23 (3) patients aged 51-60 years with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease received i.v. BU 1 mg/kg every 6 h Â 14 doses on days À9 through À6 with target concentration at steady state of X800 ng/ml based on first dose pharmacokinetics, etoposide 60 mg/kg on day À5, CY 45 mg/kg per day Â 2 days on day À3 and day À2.
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Immunosuppression
Sirolimus was begun on day À3 with a 12 mg oral loading dose followed by 4 mg/day orally for adults. Sirolimus doses were adjusted to achieve the target serum trough level of 3-12 ng/mL with tablet or liquid formulations of the drug. MMF was begun i.v. on day 0 at 15 mg/kg (based on actual body weight, unless X15 kg above ideal body weight, then adjusted ideal body weight was used) twice daily X2 h after the completion of the donor cell infusion. MMF was changed to oral dosing on recovery of regimenrelated gastrointestinal toxicities. MMF doses were not adjusted based on serum MPA levels. Tapering of sirolimus and MMF began after day 100 post HCT with the target day of discontinuation of each drug by 6 months post HCT. In the absence of GVHD or relapse of hematological disease, sirolimus and MMF were ideally tapered in an alternate manner every other week until simultaneous discontinuation of each drug.
Hematopoietic cell collection and infusion HLA compatibility was determined by serological or molecular methods for HLA class I Ags and at least lowresolution molecular typing for HLA class II Ags. HLAmatched donors received G-CSF at a dose of 16 mcg/kg per day s.c. on day À5 with apheresis begun on day À1. The cell goal was 5 Â 10 6 CD34 þ cells/kg of recipient weight with a minimum dose of 2 Â 10 6 CD34 þ cells/kg of recipient weight required for the allografting procedure.
Supportive care
Supportive care was administered by our institutional guidelines as previously described. 22 Antifungal therapy with fluconazole 400 mg/day was planned as previously described, however, with the marked elevation of sirolimus drug levels soon after fluconazole administration in the first two patients, the routine antifungal prophylaxis was changed to ambisome 5 mg/kg three times a week beginning at day þ 1 until day þ 75. All patients received ursodeoxycholic 6 mg/kg per day as hepatic SOS prophylaxis until day þ 90.
Toxicity and study definitions
The diagnosis of TMA was based on the BMT Clinical Trials Network Toxicity Committee Consensus Summary on TMA. 25 Hyperlipidemia was monitored via fasting lipid panel before and at 1-month intervals for the first 3 months after transplantation. The diagnosis of SOS was based on the Baltimore criteria. 26 The time to WBC engraftment was defined by the first of 3 consecutive days when the ANC reached 0.5 Â 10 9 /L. Platelet engraftment was defined as the first of 7 days of platelets 420 000/ mL without transfusional support. The diagnosis and grading of AGVHD was based on the consensus criteria. 27 Chronic GVHD was diagnosed based on the criteria recommended by the National Institute of Health Consensus Conference. 28 Non-relapse mortality was defined as death due to any cause other than relapse. Diseasefree survival was determined from day of transplantation (day 0) to date of relapse of disease. OS was determined from day of transplantation to date of death or last follow-up.
Pharmacokinetics of MMF
MPA area under the curve (AUC) was measured for each patient on day þ 2 and day þ 21. With i.v. administration, samples were obtained at predose 1, 2, 4, 6, 8, 10 and 12 h after morning dose and with p.o. administration, samples were obtained at predose 1, 3, 4, 6 and 8 h after morning dose. The 8 h sample on day þ 21 was excluded if not feasible to obtain while the patient was an outpatient. The MPA concentrations were carried out via Mayo Clinic laboratories, Rochester, Minnesota. Non-compartmental analysis of the concentration-time data was performed using WinNonlin, as previously described. 29 The MPA AUC was calculated if X4 concentration-time points were above the limit of quantitation, which occurred in 7 of the 11 patients.
Analysis of FoxP3 expressing CD4
þ CD25 þ T reg cells Analysis of FoxP3 expressing CD4 þ cells was carried out on G-CSF-mobilized PB of the donor as well as the PB of the recipients post transplant at months 1 and 2, 100 days, months 6, 9, 12 and 24. CD4 þ FoxP3 þ T reg cell enumeration was carried out by immunofluorescent staining of intracellular FoxP3. Fresh PBMC were prepared by FicollHypaque density-gradient centrifugation and frozen in FCS þ 10% DMSO. PBMC were thawed at 37 1C, washed once in RPMI and resuspended in cold staining buffer at a concentration of 1 Â 10 7 cells/mL. The following antibodies were added to each sample: CD45-FITC, CD4-PE, CD19-PECy5, CD3-PECy7 and CD8 APC-Cy7 (Becton Dickinson, San Jose, CA, USA). The cells were incubated in the dark on ice for 30 min and 1 mL of staining buffer was added. The cells were collected by centrifugation and resuspended in 1 mL of cold Fix/Perm buffer (Ebioscience, San Diego, CA, USA), vortexed and incubated at 4 1C for 30-60 min in the dark. The fixed cells were collected by centrifugation and resuspended in 1 mL of permeablization buffer. Blocking was performed with 2% normal rat serum in B100 mL permeablization buffer for 15 min. A 20 mL of APC-conjugated FoxP3 Ab or the APC-conjugated rat IgG2a isotype control Ab (eBiosciences, San Deigo, CA, USA) was added and incubated for 30-60 min at 4 1C in the dark. Cells were washed in permeablization buffer, centrifuged and resuspended in staining buffer for flow cytometric analysis. Stained cells were analyzed on a Becton Dickinson Influx flow cytometer (Becton-Dickinson). The number of FoxP3 expressing CD4 þ cells were assessed serially and compared with the absolute number of CD4 þ and CD8 þ conventional T con cells. Both absolute numbers and the ratio of T reg :T conv were enumerated and analyzed according to GVHD prophylactic protocol administered as well as clinical responses.
Statistical methods
The study was designed as a phase II trial with the original accrual goal of 38 patients based on the projection that the combination of sirolimus and MMF would reduce the rate of grade II-IV AGVHD from the historical expectation of X40 to p20%, with a two-sided a of 0.1 and 90% power. With the use of the Simon two-stage design, 30 the study was planned in two stages with discontinuation of the study if X5 of the first 11 patients enrolled were diagnosed with grade II-IV AGVHD. The patient characteristics and outcomes of the study and control groups were statistically analyzed via the Fischer's exact test for categorical variables and via the Mann-Whitney U-test for continuous variables. The statistical analysis of the CD4FoxP3:CD4 ratios of study patients compared with control patients was a test by linear mixed effects (LairdWare) model.
Results
Patient characteristics
In all, 11 adult patients were enrolled in this clinical protocol from October 2006 through July 2007. All patients had high-risk disease at the time of HCT based on the age, status or type of disease, with a median age of 51 years (range 26-59 years). In all, 8 of 11 patients had persistent evidence of their primary hematological malignancy at the time of transplant. The study and control patient characteristics and outcomes are summarized in Table 1 . The study and control patient groups differed significantly in their median age (P ¼ 0.0017), type of preparative regimen (P ¼ 0.0016) and number of MDS patients (P ¼ 0.007).
Engraftment
Median time to ANC 4500/mL was 12 days (range 10-19 days) in eleven patients and median time to platelet engraftment was 16 days (14-66 days) in 10 patients with platelet engraftment not reached at the time of death in one patient. Toxicity Table 2 summarizes the study treatment courses and outcomes of the patients. Four patients required discontinuation of sirolimus due to presumed sirolimus-related toxicities (study patient number (SPN) 3704 and 3888), risk of poor wound healing (SPN 3717) or inability to continue oral medication because of the altered mental status (SPN 3783). Sirolimus was replaced with FK506 in three of the four cases with MMF continued in all cases. All of the patients requiring discontinuation of sirolimus had received a BU-containing preparative regimen. The median and range of sirolimus levels of each patient are included in Table 2 . There was no correlation between maximum or median sirolimus levels and development of the toxicities requiring discontinuation of sirolimus or the diagnosis of AGVHD. The median sirolimus level on day 0 was 6.2 ng/ mL (range o2.5-27.3) in all patients. The two patients requiring discontinuation of sirolimus due to liver toxicity had levels on day 0 of 24.1 ng/mL and o2.5 ng/mL, respectively. There were no cases of TMA identified. Maximum triglyceride levels post HCT ranged from 99 to 621 mg/dL, responsive to lipid-lowering agents when appropriate.
The median MPA AUC of all patients was 12.8 mcg Â h/ mL (range: 6.4-17.4) at day þ 2 and 17.9 mcg Â h/mL at day þ 21 (range 8.0-26.6). The median MPA-glucuronide AUC was 324.8 mcg Â h/mL (range: 176-463.7) at day þ 2 and 553.6 mcg Â h/mL (range: 72-1311) at day þ 21.
GVHD
In all, 6 of the 11 patients developed grade II-IV AGVHD at a median onset of 15.5 days (range 11-18 days) post HCT. The 5th case of grade X2 AGVHD (SPN 3878) occurred after the 10th (SPN 3888) and 11th (SPN 3889) patients had begun their preparative regimens with the 11th patient subsequently developing grade 4 AGVHD. All patients received solumedrol at 2 mg/kg per day as primary AGVHD therapy with three patients receiving extracorporeal photopheresis as second-or third-line AGVHD therapy. Two of the patients (SPN 3822 and 3838) that developed grade I AGVHD of the skin responded to a o1 week course of corticosteroid therapy. Two of the three patients with grade IV AGVHD (SPN 3704 and 3783) required sirolimus discontinuation by day 9 post HCT because of severe SOS and progressive altered mental status, respectively. In both cases, sirolimus was replaced by FK506 with subsequent development of AGVHD on days 25 and 24 post HCT, respectively. The third patient (SPN 3889) was switched to FK506 from sirolimus after the onset of grade IV AGVHD, as a second-line treatment for AGVHD without evidence of sirolimus toxicity. All patients with AGVHD had partial or complete responses to GVHD therapy without GVHD-related deaths. Eight of the nine patients surviving beyond 100 days developed chronic GVHD, a median of 224 days (range 135-668 days) post HCT, two with extensive and six with limited chronic GVHD. Seven of the eight patients with chronic GVHD remain alive at a median follow-up of 40 months (range 10-46.6 months) with one dying of AML relapse at 304 days post HCT. The median Karnofsky performance status of the surviving patients was 90% (range 80-100%) at last follow-up. 
Analysis of FoxP3 expressing CD4
þ T cells FoxP3 þ cell populations in the PB were analyzed in the G-CSF-mobilized graft and after HCT in 9 of the 11 study patients receiving sirolimus and MMF as well as in the 15 control patients receiving cyclosporin-containing GVHD prophylaxis. There was a highly statistically significant increase in the ratio of CD4 þ FoxP3 þ T reg cells to CD4 þ Foxp3 À conventional T cells between the MMF/ sirolimus study patients and the CNI-containing GVHD prophylaxis control patients (Po0.0001; Figure 1) . A test by linear mixed effects (Laird-Ware) model yielded a highly significant divergence in average within-patient slope over time between the two GVHD prophylaxis groups. By 50 days post HCT, the divergence was 7.5% with a s.e. of 1%. The linear mixed effects analysis corrected for withinsubject correlation by including a random intercept for patients. A more conservative analysis was based on taking a summary of the trajectory for each patient and comparing those summaries by two-group t-test. Analyses of both the within patient maximum and mean were consistent with the linear mixed effect analysis, and yielded statistically significant differences. The incidences of AGVHD for the study and control patients are summarized in Table 1 . The absolute number of CD4 þ FoxP3 þ T reg cells was also greater in the sirolimus/MMF patients compared with the control patients, median of 40/mL (2-317) and 14/mL (range 0.4-53), respectively. In the sirolimus/MMF group, the absolute number of CD4 þ FoxP3 þ T reg cells was greater in the patients without grade 2-4 AGVHD (54, range 11-317) compared with the patients with grade 2-4 AGVHD (28.5, range 2-58) however, this difference was not seen in the control group patients nor when both patient groups were combined. There was no clear relationship between the ratios of CD4 þ FoxP3 þ T reg cells to CD4 þ Foxp3 À conventional T cells and the development of GVHD in either cohort of patients.
Survival
In all, 7 of the 11 study patients remained alive (Table 2) . Four patients have died, two because of relapse at 104 and 304 days post HCT, one because of sepsis associated with colonic perforation 54 days post HCT and one because of uterine leiomyosarcoma 713 days post HCT, diagnosed approximately at 530 days post HCT. The median diseasefree survival and OS of all living patients is 41 months (34-47 months). The survival data of the study and control patients are summarized in Table 1 .
Discussion
Sirolimus and MMF is a novel GVHD prophylactic regimen with a compilation of toxicities projected to be less limiting than CNIs or MTX. This prophylactic regimen also has the possible benefits of maintaining or increasing the FoxP3 expressing regulatory T-cell population compared with CNIs. 31 The use of sirolimus and MMF as GVHD prophylaxis in this pilot trial of myeloablative HCT patients was associated with AGVHD in 6 of the 11 patients enrolled. Although there was not a reduced incidence of AGVHD compared with expectations with standard GVHD prophylactic regimens, remarkably, 7 of these 11 high risk patients remained alive and relapse-free at a median follow-up of over 3.5 years.
The expected toxicities associated with sirolimus from the non-HCT experience include hyperlipidemias, mild cytopenias, interstitial pneumonitis and poor wound healing. [32] [33] [34] Renal insufficiency has not been associated with the use of sirolimus alone, however, there is evidence sirolimus potentiates the nephrotoxicity of CSP and FK506. [35] [36] [37] [38] [39] [40] In fact, a notable incidence of renal insufficiency and TMA with the combination of sirolimus and CNIs has been reported in the setting of prophylaxis and treatment of steroid refractory AGVHD and chronic GVHD. 2, [7] [8] [9] 41 The more recent use of sirolimus and FK506 as GVHD prophylaxis in myeloablative HCT has shown a low incidence of grade II-IV AGVHD of 20.5% with minimal need for drug removal because of the toxicities. 3 These investigators, however, reported an increased risk of TMA with sirolimus and FK506 when compared historically with FK506 and MTX. 8 In addition there was an increased risk of SOS, most marked with the combination of sirolimus and BU-containing myeloablative preparative regimens, 10 similar to our experience. In this study, sirolimus was discontinued after transplantation in four patients, three because of toxicities including severe SOS, hepatic vein thrombosis and unexplained altered mental status. There was no evidence of Post BMT days TMA and only one episode of reversible acute renal failure in association with severe SOS, supporting the expectation of minimal risk of TMA or renal toxicity when sirolimus is administered without a CNI. Of interest, severe AGVHD occurred in two of four patients after early discontinuation of sirolimus, likely raising their risk of developing AGVHD. On the basis of our current experience of severe toxicities leading to sirolimus removal only in the patients receiving the BU-containing preparative regimen and the recent evidence from other investigators reporting an increased risk of SOS with sirolimus or everolimus and BU combinations, 10,42 the use of sirolimus in conjunction with BU should be contraindicated. Supratherapeutic sirolimus levels were not clearly predictive of toxicity in our patient cohort, however, close monitoring of sirolimus levels are likely important in preventing sirolimusassociated toxicities as well.
Sirolimus and less so MMF have been shown to augment or maintain regulatory T-cell populations in animal models and human studies. 43, 44 In our study, the T reg :CD4 ratios in the GCSF mobilized PB of the donors and PB of the control group patients were similar to what has been previously reported from unmobilized PB of donors and post-HCT patients (0-10%). 47, 48 There was a statistically significant increase in the T reg :CD4 ratio in the PB of patients receiving sirolimus-MMF vs CSP-containing GVHD prophylactic regimens. Of note, the study and control groups, chosen based on their GVHD prophylaxis regimens, differed significantly in their median age, number of patients with MDS and the preparative regimens. Hence, one cannot definitively state that the GVHD prophylactic regimen was the only factor effecting the difference in the T reg :CD4 þ ratios between the patient groups. The T reg :CD4 þ ratios between and within each patient group did not clearly correlate with the development or severity of AGVHD, perhaps explained by the limited number of patients available for analysis and/or the differences in the patient characteristics. It is possible, monitoring the T reg :CD4 þ ratios more frequently than monthly would have allowed a more ideal opportunity for intrapatient comparison, that is, before and after onset of AGVHD, or during AGVHD treatment and response. Interestingly, patients requiring sirolimus removal had persistently increased T reg :CD4 þ ratios, however, these patients were also receiving extracorporeal photopheresis as AGVHD therapy. There are now multiple reports in animal and human settings of extracorporeal photopheresis affecting the T-regulatory cell population in the PB, 45, 46 hence the use of extracorporeal photopheresis may have impacted the T reg :CD4 þ ratio in our patients.
The MMF pharmacokinetics of our study revealed low AUCs of the active metabolite of MMF, MPA, compared with reports in the HCT literature. 19, 49, 50 Although there is no clear correlation between MPA AUC or MPA trough levels and efficacy, these low levels may have contributed to the moderate incidence of AGVHD in this trial. There were no definitive MMF-associated toxicities appreciated in this trial, although the one case of cecal ulceration and perforation is a reported toxicity of MMF described in the solid organ transplantation literature. 51 Of note, the combination of sirolimus and MMF did not seem to delay ANC recovery in this trial. Given the low MPA levels and lack of definitive MMF toxicity in this preliminary trial, it may be beneficial to incorporate a higher daily dose of MMF via an every 8 h regimen.
Offering the patient with high-risk hematological malignancy a curative therapy is severely limited by the risk of relapse of disease, regimen-and GVHD-related morbidity and mortality. Despite our preliminary experience showing lack of reduction of AGVHD and regimen-related toxicity of MMF and sirolimus with the preparative regimens used, there remained remarkably low non-relapse mortality and 7 of 11 patients were disease-free at a median follow-up of over 3.5 years. Further study of the MMF and sirolimus combination could be pursued with the use of increased dosing of MMF but with the need to avoid BU-containing preparative regimens. Continuing the prospective monitoring of T reg :CD4 þ ratios in GVHD studies is necessary to further understand the impact of T-regulatory cells on GVHD.
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